Data and Code for: Private and Social Returns to R&D: Drug Development and Demographics
Principal Investigator(s): View help for Principal Investigator(s) Efraim Benmelech, Northwestern University; Joshua Krieger, Harvard University; Dimitris Papanikolauo, Northwestern; Janice Eberly, Northwestern University
Version: View help for Version V1
Name | File Type | Size | Last Modified |
---|---|---|---|
scripts | 04/30/2021 08:00:PM | ||
README_AEA_DataReplicationFiles_4.30.21.docx | application/vnd.openxmlformats-officedocument.wordprocessingml.document | 26.7 KB | 04/30/2021 04:01:PM |
README_AEA_DataReplicationFiles_4.30.21.pdf | application/pdf | 248.9 KB | 07/13/2021 07:21:AM |
proprietary_data_readme.txt | text/plain | 526 bytes | 02/26/2021 06:21:AM |
public_data_readme.txt | text/plain | 877 bytes | 04/30/2021 03:59:PM |
Project Citation:
Project Description
The five figures in the paper come from a 3 distinct data sources: 1) The Medical Expenditures Panel Survey (MEPs), a publicly available large-scale survey of families and individuals, medical providers and employers in the United States 2) Cortellis Investigational Drugs, a private industry intelligence data provider covering drug development, and 3) Compustat
Scope of Project
D24 Production; Cost; Capital; Capital, Total Factor, and Multifactor Productivity; Capacity
J11 Demographic Trends, Macroeconomic Effects, and Forecasts
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
O31 Innovation and Invention: Processes and Incentives
Related Publications
Published Versions
Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.
This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.